

## Dear Colleague,

We look forward to your participation at the upcoming NCI Head and Neck Steering Committee (HNSC) Clinical Trials Planning Meeting (CTPM) on High-Risk Resectable/Advanced-Unresectable Cutaneous Squamous Cell Cancer (cSCC) which will be taking place as a hybrid meeting on Thursday, January 12, 2023 and Friday, January 13, 2023. A draft agenda is a attached for your reference.

Participation in this meeting is by invitation only. Please go to <a href="https://events.cancer.gov/nci/cSCCctpm2023/registration">https://events.cancer.gov/nci/cSCCctpm2023/registration</a> to register for this meeting so that we can plan for your attendance and participation. Your response is kindly requested no later than <a href="https://events.cancer.gov/nci/cSCCctpm2023/registration">https://events.cancer.gov/nci/cSCCctpm2023/registration</a> to register for this meeting so that we can plan for your attendance and participation. Your response is kindly requested no later than <a href="https://events.cancer.gov/nci/cSCCctpm2023/registration">https://events.cancer.gov/nci/cSCCctpm2023/registration</a> to register for this meeting so that we can plan for your attendance and participation. Your response is kindly requested no later than <a href="https://events.cancer.gov/nci/cSCCctpm2023/registration">https://events.cancer.gov/nci/cSCCctpm2023/registration</a> to register for this meeting so that we can plan for your attendance and participation. Your response is kindly requested no later than <a href="https://events.cancer.gov/nci/cSCCctpm2023/registration">https://events.cancer.gov/nci/cSCcctpm2023/registration</a> to register for this meeting so that we can plan for your attendance and the participation of the participation o

Additional meeting materials and logistics will be provided closer to the meeting date and only to registered participants.

The objective of this meeting is to develop clinical trial ideas that can be conducted through the NCI's Clinical Trial Network (NCTN) groups in the following two populations:

- 1) High Risk Resectable Disease in Immunosuppressed Population:
  - Explore embedding agents that are safe in this population in conjunction with surgery and radiation.
- 2) Recurrent/Metastatic Disease in Immunosuppressed Population:
  - Novel agent(s) for patients traditionally not eligible for immunotherapy for which there are limited options.

We look forward to seeing you in January. Please feel free to contact me with any questions.

## Mehrdad Mohseni M.D.

Program Director CCCT/ NCI / NIH mohsenim@nih.gov